Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Tumor-associated macrophages affect tumor progression and resistance to immune checkpoint therapy. Here, we identify the chemokine signal regulator FROUNT as a target to control tumor-associated macrophages. The low level FROUNT expression in patients with cancer correlates with better clinical outcomes. Frount-deficiency markedly reduces tumor progression and decreases macrophage tumor-promoting activity. FROUNT is highly expressed in macrophages, and its myeloid-specific deletion impairs tumor growth. Further, the anti-alcoholism drug disulfiram (DSF) acts as a potent inhibitor of FROUNT. DSF interferes with FROUNT-chemokine receptor interactions via direct binding to a specific site of the chemokine receptor-binding domain of FROUNT, leading to inhibition of macrophage responses. DSF monotherapy reduces tumor progression and decreases macrophage tumor-promoting activity, as seen in the case of Frount-deficiency. Moreover, co-treatment with DSF and an immune checkpoint antibody synergistically inhibits tumor growth. Thus, inhibition of FROUNT by DSF represents a promising strategy for macrophage-targeted cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
A Direct Approach to False Discovery Rates
Storey, J. D. (2002) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00346 · Cited by 5,603
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Skrott, Z., Mistrik, M., Andersen, K. K., Friis, S., Majera, D., Gursky, J., Ozdian, T., Bartkova, J., Turi, Z., Moudry, P., et al. (2017) · Nature · doi:10.1038/nature25016 · Cited by 807
Qian, B., Deng, Y., Im, J. H., Muschel, R. J., Zou, Y., Li, J., Lang, R. A., & Pollard, J. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006562 · Cited by 664
Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367
Cited by
Lu, Y., Pan, Q., Gao, W., Pu, Y., Luo, K., He, B., & Gu, Z. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121335 · Cited by 149
Lei, Y., Tang, L., Chen, Q., Wu, L., He, W., Tu, D., Wang, S., Chen, Y., Liu, S., Xie, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34671-1 · Cited by 104
Wang, Q., Zhu, T., Miao, N., Qu, Y., Wang, Z., Chao, Y., Wang, J., Wu, W., Xu, X., Xu, C., et al. (2022) · The EMBO Journal · doi:10.15252/embj.2022110636 · Cited by 45
Okabe, Y., Toda, E., Urushiyama, H., Terashima, Y., Kunugi, S., Kajimoto, Y., Terasaki, M., Matsushima, K., Saito, A., Yamauchi, Y., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-71770-z · Cited by 14
“These results are consistent with previous studies reporting that DSF and its metabolites have the potential to inhibit the FROUNT/CCR2 interaction, with DSF having the highest activity over its metabolites 8 .”
InfluentialSelf-citationFlores-López, L. A., De la Mora-De la Mora, I., Malagón-Reyes, C. M., García-Torres, I., Martínez-Pérez, Y., López-Herrera, G., Hernández-Alcántara, G., León-Avila, G., López-Velázquez, G., Olaya-Vargas, A., et al. (2024) · Biomolecules · doi:10.3390/biom14101295 · Cited by 6
Metadata
- Authors
- Terashima, Y., Toda, E., Itakura, M., Otsuji, M., Yoshinaga, S., Okumura, K., Shand, F. H. W., Komohara, Y., Takeda, M., Kokubo, K., Chen, M.-C., Yokoi, S., Rokutan, H., Kofuku, Y., Ohnishi, K., Ohira, M., Iizasa, T., Nakano, H., Okabe, T., Kojima, H., Shimizu, A., Kanegasaki, S., Zhang, M.-R., Shimada, I., Nagase, H., Terasawa, H., & Matsushima, K.
- Venue
- Nature Communications
- Published
- 2020-01-30
- Volume
- 11
- Issue
- 1
- Pages
- 609-609
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W3003330162
- Cited by
- 101
- References
- 10
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties. https://app.cochat.ai/papers/10.1038/s41467-020-14338-5
- The paper
- Terashima, Y., Toda, E., Itakura, M., Otsuji, M., Yoshinaga, S., Okumura, K., Shand, F. H. W., Komohara, Y., Takeda, M., Kokubo, K., Chen, M.-C., Yokoi, S., Rokutan, H., Kofuku, Y., Ohnishi, K., Ohira, M., Iizasa, T., Nakano, H., Okabe, T., . . . Matsushima, K. (2020). Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties. Nature Communications. https://doi.org/10.1038/s41467-020-14338-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.